Considering that angiogenesis inhibitors and ICIs are used for anticancer therapies against advanced HCC, Kimura T and colleagues also reported that VEGFR inhibitor Levantinib enhanced the antitumor activity of PD-1 blockade, decreasing the proportion of the monocyte and macrophage population and increasing CD8+ T cell populations in the Hepa1-6 mouse HCC syngeneic model [135]. This evidence concerns the gene CD8A and hepatocellular carcinoma.